phosphatidylinositol specific phospholipase C X domain containing 3Genealiases: []
Q-omics provides the consensus-scored PLCXD3 profile across patient tissues and cancer cell-line models. PLCXD3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLCXD3 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, PLCXD3 protein abundance shows 23,557 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRP, and GBM as cancer lineages where PLCXD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCXD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCXD3 survival associations across molecular data types. PLCXD3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCXD3 RNA expression–survival associations across cancer types. High PLCXD3 expression shows unfavorable associations in UVM, STAD and LUSC, but favorable associations in ACC, KIRC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PLCXD3 RNA expression.
This table summarizes PLCXD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLCXD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCXD3 shows lower tumor expression in KIRP, COAD, KIRC, THCA, UCEC and STAD. The KIRP box plot shows higher PLCXD3 RNA expression in normal versus tumor tissue (log2 FC = −2.714, t-test p < 0.001).
This table shows molecular features associated with PLCXD3 in patient tissues and cancer cell lines. In patient samples, PLCXD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCXD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
